Physician profile
Patrick L Allen
NPI 1053369348
$2,232.57
in general payments reported to CMS, 2019-2025
29 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $276 · 2021: $322 · 2022: $270 · 2023: $612 · 2024: $345 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,168.58 | 2019-2024 | Lo Loestrin Fe, Teflaro, Dalvance |
| Mayne Pharma Commercial LLC | $167.27 | 2022-2025 | |
| Allergan, INC. | $99.20 | 2019-2020 | |
| Exact Sciences Corporation | $98.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lupin INC. | $74.49 | 2019-2021 | |
| Myovant Sciences INC. | $65.28 | 2021-2022 | |
| Therapeuticsmd, INC. | $64.93 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $41.98 | 2023 | Myfembree |
| Organon LLC | $41.44 | 2021-2022 | |
| Scynexis, INC. | $40.85 | 2022 | |
| Pfizer INC. | $37.65 | 2023 | |
| Lilly USA, LLC | $29.99 | 2025 | Zepbound |
| Avion Pharmaceuticals | $29.26 | 2020 | |
| Novo Nordisk INC | $28.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.81 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $22.29 | 2023 | Accrufer |
| Hologic Sales and Service, LLC | $21.77 | 2022 | |
| Lsi Solutions INC | $20.62 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $19.11 | 2023 | Vivjoa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.61 | 2022 | |
| Evofem Biosciences, INC. | $17.98 | 2020 | |
| Merck Sharp & Dohme LLC | $17.75 | 2019 | |
| Ethicon US, LLC | $16.68 | 2020 | |
| Nestle Healthcare Nutrition INC. | $16.07 | 2021 | |
| Aspira Women'S Health INC | $13.88 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.00 | 2023 | Adthyza |
| Ironwood Pharmaceuticals, INC | $12.46 | 2020 | |
| Coopersurgical, INC. | $10.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.